Intuitive Surgical, Inc. (ISRG) is the world’s leading provider of minimally invasive surgical robotics, best known for its da Vinci surgical system. The company’s business model centers on three interrelated streams: (1) the sale of advanced robotic platforms to hospitals and surgical centers; (2) the sale of proprietary accessories and consumables—such as instruments, staplers, and energy‑based devices—required for each procedure; and (3) a high‑margin service and support business that includes maintenance contracts, training, and software updates. This “hardware‑plus‑recurring‑consumables” structure creates a strong, expanding revenue base and drives customer lock‑in, as hospitals tend to adopt multiple robotic systems once they have invested in the platform and its ecosystem.

Financially, Intuitive Surgical has demonstrated robust growth over the past several years. Revenue rose from roughly $6.2 billion in 2022 to $7.1 billion in 2023 and is projected to exceed $10 billion by 2025, reflecting a compound annual growth rate of about 17 %. Contribution profit, a key metric of operating efficiency, grew from $4.2 billion in 2022 to $7.1 billion in 2025, pushing the contribution margin upward from 66 % to nearly 69 % by 2027. EBITDA margin expanded dramatically, climbing from 31 % in 2022 to an anticipated 46 % by 2027, underscoring the scalability of the company’s operating leverage. EBITDA itself is expected to surpass $5 billion by 2025, driven by both higher sales volumes and improved cost control.

Profitability metrics are equally encouraging. Earnings per share (EPS) have risen from $3.72 in 2022 to $8.48 in 2025, with analysts projecting EPS above $9 by 2027. The price‑to‑earnings ratio, while historically elevated—peaking near 81 in 2024—has moderated to the mid‑60s range, reflecting a more balanced market valuation as earnings grow faster than price appreciation. SG&A expenses have been steadily declining as a percentage of revenue, falling from 28 % in 2022 to just over 22 % in 2027, further easing the cost burden on the business.

In terms of market position, Intuitive Surgical enjoys a dominant share of the robotic‑assisted surgery market, with few direct competitors capable of matching its technology breadth, service infrastructure, and brand recognition. The company’s installed base of over 6,000 systems worldwide provides a sizable platform for future upgrades and consumable sales. Competitive barriers—including extensive surgeon training, a robust ecosystem of accessories, and a strong clinical data foundation—help protect its market share against potential entrants. Overall, Intuitive Surgical’s combination of accelerating revenue, expanding margins, and recurring consumable demand positions it for sustained growth and makes it a standout player in the medical‑technology sector.

Intuitive Surgical (ISRG) continues to expand its market‑leading robotic‑assisted surgery platform, with revenue projected to climb from $6.22 bn in 2022 to $11.65 bn by 2027, delivering a compound annual growth rate of roughly 17 %. The top‑line surge is underpinned by accelerating adoption of the da Vinci system in both established and emerging markets, as hospitals increasingly shift to minimally invasive procedures that promise faster recovery and lower total cost of care.

Profitability has improved markedly. Contribution margin steadied around 67 % and is expected to rise toward 69 % by 2027, while EBITDA margin expands from 31 % in 2022 to an anticipated 46‑47 % in 2026‑27, reflecting disciplined cost management and higher‑margin service and instrument sales. SG&A as a share of revenue has been trimmed from 28 % to just above 22 % over the same period, further easing the expense burden.

Earnings per share are forecast to rise from $3.72 in 2022 to $9.54 by 2027, while the price‑to‑earnings multiple remains in the 60‑70 range, indicating that the market still values growth at a premium but is beginning to converge with more traditional valuation levels.

Looking ahead, the primary growth drivers are continued geographic penetration, expansion of the instrument‑and‑service ecosystem, and the rollout of next‑generation robotic platforms that broaden clinical indications. Management expects revenue growth to moderate to a still‑robust 4‑6 % annual pace beyond 2025, supported by a strong pipeline of new products and sustained hospital capital spending. The company’s cash conversion remains healthy, enabling ongoing investment in research, sales, and service capacity. Overall, Intuitive Surgical’s combination of accelerating margins, rising cash flow, and a durable competitive moat positions it for sustained outperformance, making it a compelling holding for investors seeking exposure to the long‑term shift toward robotic minimally invasive surgery.

Intuitive Surgical trades at a trailing PE of roughly 68‑x, modestly above the median medical‑device peer group, which typically hovers in the 55‑65 range. The forward‑looking PE of 61‑x on the 2026‑27 earnings trajectory suggests a premium that is justified only if the company can sustain its double‑digit revenue growth and expanding contribution margins. Over the next four years the model projects a CAGR of about 17 % in revenue, driven by continued adoption of robotic platforms and ancillary services. Contribution margin is expected to creep upward to the high‑60 % level, while EBITDA margin could breach 45 % by 2027, outpacing the average peer EBITDA margin of roughly 30‑35 %.

Operating leverage is evident: SG&A as a share of revenue falls from 27.6 % in 2023 to just above 22 % by 2027, pulling contribution profit from $4.7 bn to $8.0 bn and lifting EBITDA from $2.2 bn to $5.5 bn. This margin expansion underpins a rising EBITDA yield of 45‑47 % in the outer years, implying an EV/EBITDA multiple of roughly 15‑16 x, which aligns with the upper end of the medical‑technology spectrum but remains defensive relative to high‑growth software peers.

Relative to peers such as Medtronic, Boston Scientific and Stryker, Intuitive’s valuation reflects a combination of higher growth, superior margins and a dominant market position in robotic surgery. Assuming the company can maintain its product pipeline and capture incremental market share, a fair‑value range of $350‑$380 per share emerges, corresponding to an EV/EBITDA multiple of 15‑16 x and a PE of 60‑65 x on 2026 earnings. Investors seeking exposure to sustained margin expansion and secular demand for minimally invasive robotics may find the current price justified, but any slowdown in growth or margin compression would quickly erode the premium.

Intuitive Surgical, Inc. demonstrates competitive positioning within its industry through consistent financial performance and strategic market positioning relative to key competitors in the sector.